Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : Receives US FDA Fast Track Designation for Potential Huntington's Disease Treatment

09/15/2021 | 07:10am EDT


ę MT Newswires 2021
All news about SAGE THERAPEUTICS, INC.
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/20SAGE THERAPEUTICS : to Report Third Quarter 2021 Financial Results on Tuesday, November 2,..
BU
10/20SAGE THERAPEUTICS : Needham Adjusts Price Target on Sage Therapeutics to $79 from $84, Kee..
MT
10/20SAGE THERAPEUTICS : and Biogen Announce Plans to Submit a New Drug Application (NDA) for Z..
AQ
10/19SAGE THERAPEUTICS : Morgan Stanley Adjusts Sage Therapeutics' Price Target to $66 from $78..
MT
10/19SAGE THERAPEUTICS : and Biogen Announce Plans to Submit a New Drug Application (NDA) for Z..
PU
10/19SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19SAGE THERAPEUTICS : Biogen Submit Depression Drug Zuranolone New Drug Application to FDA
MT
10/19Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022
DJ
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 7,58 M - -
Net income 2021 -426 M - -
Net cash 2021 1 445 M - -
P/E ratio 2021 -5,69x
Yield 2021 -
Capitalization 2 432 M 2 432 M -
EV / Sales 2021 130x
EV / Sales 2022 11,8x
Nbr of Employees 298
Free-Float 87,6%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 41,35 $
Average target price 77,60 $
Spread / Average Target 87,7%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-52.20%2 437
GILEAD SCIENCES, INC.16.25%84 845
BIONTECH SE258.67%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS22.57%59 906
VERTEX PHARMACEUTICALS-22.12%47 992